1. 321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer. (9th November 2020) Authors: Gandhi, Shipra; Opyrchal, Mateusz; Ford, Cayla; Fitzpatrick, Victoria; Grimm, Melissa; Basse, Per; Quinn, Marie; Witkiewicz, Agnieszka; Attwood, Kristopher; Ernstoff, Marc; O'Connor, Tracey; Early, Amy; Levine, Ellis; Kalinski, Pawel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer. (9th November 2020) Authors: Gandhi, Shipra; Opyrchal, Mateusz; Ford, Cayla; Fitzpatrick, Victoria; Grimm, Melissa; Basse, Per; Quinn, Marie; Witkiewicz, Agnieszka; Attwood, Kristopher; Ernstoff, Marc; O'Connor, Tracey; Early, Amy; Levine, Ellis; Kalinski, Pawel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗